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Abstract
Background: To evaluate the impact of the duration of chronic inflammation on gene expression
in skeletal muscle biopsies (MBx) from untreated children with juvenile dermatomyositis (JDM) and
identify genes and biological processes associated with the disease progression, expression profiling
data from 16 girls with active symptoms of JDM greater than or equal to 2 months were compared
with 3 girls with active symptoms less than 2 months.
Results: Seventy-nine genes were differentially expressed between the groups with long or short
duration of untreated disease. Genes involved in immune responses and vasculature remodelling
were expressed at a higher level in muscle biopsies from children with greater or equal to 2 months
of symptoms, while genes involved in stress responses and protein turnover were expressed at a
lower level. Among the 79 genes, expression of 9 genes showed a significant linear regression
relationship with the duration of untreated disease. Five differentially expressed genes – HLA-
DQA1, smooth muscle myosin heavy chain, clusterin, plexin D1 and tenomodulin – were verified
by quantitative RT-PCR. The chronic inflammation of longer disease duration was also associated
with increased DC-LAMP+  and BDCA2+  mature dendritic cells, identified by
immunohistochemistry.
Conclusion: We conclude that chronic inflammation alters the gene expression patterns in
muscle of untreated children with JDM. Symptoms lasting greater or equal to 2 months were
associated with dendritic cell maturation and anti-angiogenic vascular remodelling, directly
contributing to disease pathophysiology.
Background
Juvenile dermatomyositis, a systemic vasculopathy, is the
most common of the inflammatory myopathies in chil-
dren and is characterized by symmetrical proximal muscle
weakness, and a pathognomonic rash, which includes a
heliotrope discoloration about the eyes, dilated capillaries
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at the nailbeds and eyelid margins, and thickened ery-
thema over the knuckles (Gottron's papules). The three
other diagnostic criteria are: serum elevation of muscle
derived enzymes, a muscle biopsy with specific histologi-
cal features that include mononuclear cell infiltrates as
well as perifasicular atrophy with evidence of an occlusive
vasculopathy, and a positive electromyogram document-
ing inflammation [1].
There is little information describing the critical variables
that influence the development and course of this often
devastating illness. Over 3.2 cases/million children/year
are diagnosed, with a 2.1 girl to 1 boy ratio [2]. At the time
of their first symptom, rash or weakness, the mean age of
the patient population is 6.7 years, while 25% of the chil-
dren are age 4 or younger. It usually takes 4 months or
more for the children to be diagnosed with JDM, when the
muscle biopsy is obtained [3]. At diagnosis, the extent and
severity of the skin and muscle inflammatory response
can be assessed using validated disease activity scores
(DAS) for skin and muscle involvement [2,4,5].
Children with JDM often have a family history of autoim-
mune disease. The frequencies of the HLA antigens
DQA1*0501, DQA1*0301, and DRB3 have been
reported to be higher in the JDM population than control
populations suggesting a genetic contribution to this dis-
order, which may be additionally influenced by the TNF-
α-308 allelic polymorphisms [6,7].
The precise stimulus initiating the inflammatory process
is not known. However, there is evidence that newly diag-
nosed children with JDM have a history of infection, often
respiratory or gastrointestinal in nature, within three
months prior to the appearance of rash or muscle weak-
ness [5]. In addition, gene expression profile data from
MRI directed diagnostic biopsies of muscle from
untreated children with active symptoms of JDM identi-
fied up-regulation of many type I interferon- (IFNα/β)
inducible genes [8]. These findings support the interpreta-
tion that the inflammatory milieu in JDM is similar to that
seen in anti-microbial responses. In that investigation we
also found a marked down-regulation of genes associated
with protein synthesis; both observations were subse-
quently confirmed in studies of muscle from adults with
DM [9].
Untreated chronic inflammation in children with JDM is
associated with the development of pathological calcifica-
tions [10]. The phenotype of the children who present in
clinic early in their disease course differs from those diag-
nosed later, both with respect to height and weight, and
specific JDM symptoms. Children diagnosed early in the
disease course are much weaker than those who have a
longer time to diagnosis [10]. However, the extent and
severity of skin involvement appears to be stable over time
[10].
With respect to diagnostic laboratory testing, serum levels
of muscle enzymes, generally used to evaluate muscle
inflammation, are more likely to be in the normal range
when blood is collected 2–4.7 months after the child's
first symptom (rash or weakness), making it more difficult
to establish a diagnosis of definite JDM [10]. The purpose
of the present study was to examine the impact of the
duration of untreated chronic inflammation on gene
expression in diagnostic muscle biopsies obtained from a
large group of untreated girls with clinical symptoms of
active JDM in order to identify genes and biological proc-
esses associated with disease progression in JDM.
Results
Demographics
All diagnostic biopsies studied were from untreated girls
who had not been given any nonsteroidal or immunosup-
pressive therapy, and for whom a Disease Activity Score
(DAS) was obtained at the time of biopsy (Table 1). The
short disease duration group (mean 0.9 ± 0.3 months)
was compared with the long duration group (mean 18 ±
27.9 months). Their ages at disease onset date were simi-
lar: 5.6 ± 1.0 years for the short duration group compared
with 5.2 ± 2.7 years for long duration group. They were
similar in disease activity scores. Total DAS for the short
duration group was 11.7 ± 4.0 (mean DAS skin 5.0 ± 1.7,
mean DAS muscle 6.7 ± 2.5) compared with the Total
DAS for the long disease duration group of 12.0 ± 3.9
(mean DAS skin, 6.2 ± 1.4, mean DAS muscle 5.8 ± 3.1).
Microarray analysis did not identify any gene significantly
differentially expressed among different genotypes (TNF-
α-308, DQA1*0301 and DQA1*0501). The second group
of girls tested for confirmation of the gene expression
changes by immunohistochemistry or RT-PCR, 5 patients
each of long and short duration of untreated disease were
also similar with respect to age at onset, race, and DAS
scores (Table 2).
Comparison of muscle biopsy gene profiles based on 
disease duration
As noted above, duration of disease, measured as more
than 2 months of symptoms is a critical variable, influenc-
ing both clinical and laboratory data [10]. Since changes
at the molecular level occur prior to phenotypic changes,
we used 2 months (≥ 2 months compared with < 2
months) as the grouping cut-off in the present study. In
order to control for gender effects, this study was limited
to girls. We identified 79 genes represented by 85 Affyme-
trix probe sets differentially expressed in the muscle sam-
ples. All genes reached statistical significance (p < 0.05)
after multiple testing correction with the false positive rate
at 5%. In addition, in order to "bracket" the optimal cut-BMC Immunology 2008, 9:43 http://www.biomedcentral.com/1471-2172/9/43
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off time we compared data from patients with disease
duration of 3 months or less with greater than 3 months,
and also compared 4 months or less with greater than 4
months. There was no significant difference in expressed
genes when the 4 month cut-off was used, and only 3
genes were differentially expressed when the 3 month cut-
off was used.
For an overview of the changes in relation to the baseline
generated using the control samples from age-matched
healthy girls undergoing cleft palate repair, we used hier-
archical clustering analysis to visualize changes of gene
expression patterns associated with the three groups (con-
trol, short and long active disease duration) (Figure 1). Six
clusters were identified by visualizing the gene tree in Fig-
ure 1. Among the 79 genes, 44 genes were expressed at a
lower level in the group with active disease greater than 2
months vs. shorter than 2 months (Figure 1, cluster A, B,
and E), while 35 genes were expressed at a higher level in
the group (Figure 1, cluster C, D, and F).
Cluster A represents genes up-regulated only in JDM
patients with short duration of active disease. Cluster B
represents genes significantly down-regulated only in
JDM patients with long duration of active JDM. Many
genes in these two clusters are involved in protein turn
over and stress responses [see Additional file 1]. Most
genes in cluster E are either encoding enzymes or proteins
with unknown functions. These genes were highly up-reg-
ulated in patients with short duration of active disease but
not in the other groups suggesting that they are activated
at the acute phase of the disease.
For genes up-regulated in patients with longer duration of
active disease (cluster C, D, and F), genes in cluster C and
D were up-regulated in both groups when compared to
healthy controls. However, the changes were significantly
higher in the patients with long duration of active disease.
Interestingly, most of the immune response genes identi-
fied in this study were grouped into these two clusters
(Table 3). While genes in cluster F were expressed at
Table 1: Demographics of children with JDM in expression profiling study.
Patient 
No.
Age at 
Onset
DAS Skin DAS Weak DAS Total Age at 
MBx
Duration of 
Untreated 
Disease 
(Months)
DQA 0301 DQA 0501 TNF Type
Short Disease Duration
1 4.7 4.0 7.0 11.0 4.8 1.1 neg pos GA
2 6.8 7.0 9.0 16.0 6.8 1.1 neg pos GG
3 5.5 4.0 4.0 8.0 5.50 0.6 neg pos GA
Mean 5.6 5.0 6.7 11.7 5.7 0.9
ST. Dev. 1.0 1.7 2.5 4.0 1.1 0.3
Long Disease Duration
4 1.0 6.0 5.5 11.5 3.5 30.6 neg pos GA
5 1.8 6.0 3.0 9.0 2.3 6.1 pos neg GG
6 8.3 9.0 10.0 19.0 8.5 2.1 neg neg GG
7 8.8 5.0 4.0 9.0 9.0 2.6 neg pos GA
8 3.9 6.0 9.0 15.0 5.2 16.1 neg neg GG
9 1.6 7.0 9.0 16.0 2.2 7.7 pos neg GG
10 7.2 8.0 6.0 14.0 7.4 2.2 pos neg GG
11 8.3 4.0 8.0 12.0 8.7 4.9 neg pos AA
12 6.0 7.0 3.0 10.0 7.7 20.6 pos pos GG
13 7.7 6.0 7.0 13.0 8.2 6.4 neg pos GG
14 2.5 3.0 1.0 4.0 3.6 13.6 neg neg GG
15 2.6 7.0 3.0 10.0 11.3 105.6 neg neg GA
16 6.1 7.0 10.0 17.0 6.6 6.6 neg neg GA
17 4.5 6.0 6.0 12.0 5.2 8.5 neg pos GG
18 5.1 6.0 8.0 14.0 10.3 63.5 neg pos AA
19 8.4 6.0 1.0 7.0 8.6 3.2 neg pos GG
Mean 5.1 6.2 5.8 12.0 6.7 18.8
ST. Dev. 2.8 1.4 3.1 3.9 2.9 27.9
DAS: disease activity score; MBx: muscle biopsy; DQA: Major histocompatibility complex, class II, DQ alpha-1; TNF type: Tumor necrosis factor -
308 allele.BMC Immunology 2008, 9:43 http://www.biomedcentral.com/1471-2172/9/43
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higher level in the group with long duration, most of the
genes in this cluster were down-regulated compared to the
baseline (Table 4). In cluster F, most genes are associated
with functions of vasculature remodelling. In this report,
we will focus on genes in cluster C, D and F (Table 3 and
4), while the complete gene list of each cluster is reported
in Additional file 1.
In a previous profiling study, we identified a list of
immune response genes differentially expressed in JDM
patients, in which many of the genes were induced by type
I interferon (IFNα/β) [8]. Although many probe sets on
the U133A microarry are different from those on the
Affymetrix FL microarray, the changes identified previ-
ously were verified using the new microarray. However we
found no differential expression of those IFN inducible
genes in the short and long disease duration group, sug-
gesting the expression of these inflammatory response
genes is independent of disease chronicity.
Infiltration of mature dendritic cells in the patients with 
longer duration of active symptoms
To interpret the changes of genes involved in immune
responses in cluster C and D (Table 3), we first searched
for genes that were highly expressed in specific immune
cell types. Although most of the genes were not specifi-
cally expressed by a single cell type, HLA-DR and glyco-
protein nmb have been shown to be highly expressed in
dendritic cells compared to B cells, monocytes and T cells
[11]. This pattern of up-regulation of the genes suggested
that there might be a higher number of dendritic cells in
the muscle of children with a longer duration of active dis-
ease.
Using qRT-PCR, we first verified the expression changes
HLA-DQA1 which could be either directly involved in
antigen presentation or a surrogate marker of an active
site. Because supply of diagnostic muscle biopsy tissue
was limited, we tested a different group of 5 girls with
short duration of disease, less than 2 months and a differ-
ent group of 3 girls with disease duration greater or equal
to 2 months, plus 2 girls from the original long disease
duration group, which had been gene profiled in this
study (Table 2).
The expression level of HLA-DQA1 was 4.28 fold (p <
0.05) up-regulated in patients with longer duration of
active disease, which verified our array data (5.6 fold, p <
0.005) (Figure 2). We then performed immunohisto-
chemistry, using an antibody directed against a dendritic
cell maturation marker, DC-LAMP to localize the cells in
the muscle tissues (Figure 3). Long disease duration JDM
patients displayed a greater overall presence of mature
dendritic cells (Figure 3A) compared to short disease
duration JDM patients (3C). Greater concentrations of
mature dendritic cells were found in perivascular regions
compared with the endomesium, In addition, many
mature dendritic cells were BDCA2 positive suggesting a
Table 2: Demographics of children with JDM in qRT-PCR validation.
Patient 
No.
Age at 
Onset
DAS Skin DAS Weak DAS Total Age at 
MBx
Duration of 
Untreated 
Disease 
(Months)
DQA 0301 DQA 0501 TNF Type
Short Disease Duration
1 6.8 5.0 9.0 14.0 6.9 1.2 neg pos GA
2 6.9 5.0 8.0 13.0 7.0 1.7 neg pos GG
3 6.1 7.0 9.0 16.0 6.3 1.8 neg pos GG
4 11.6 5.0 8.0 13.0 11.7 1.0 neg pos GG
5 8.9 5.0 7.0 12.0 9.0 1.5 neg pos GG
Mean 8.1 5.4 8.2 13.6 8.2 1.4
ST. Dev. 2.2 0.9 0.8 1.5 2.2 0.4
Long Disease Duration
6 8.5 6.0 7.0 13.0 9.6 12.9 neg neg GG
7 5.6 8.0 8.0 16.0 5.9 4.0 neg pos GA
8 8.3 4.0 8.0 12.0 8.7 4.9 neg pos AA
9 7.7 6.0 7.0 13.0 8.2 6.4 neg pos GG
10 14.7 5.0 10.0 15.0 15.2 5.9 neg pos GG
Mean 9.0 5.8 8.0 13.8 9.5 6.8
ST. Dev. 3.4 1.5 1.2 1.6 3.5 3.5
DAS: disease activity score; MBx: muscle biopsy; DQA: Major histocompatibility complex, class II, DQ alpha-1; TNF type: Tumor necrosis factor -
308 allele.BMC Immunology 2008, 9:43 http://www.biomedcentral.com/1471-2172/9/43
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plasmacytoid origin. No significant differences were
found in the distribution of the BDCA2 positive plasma-
cytoid dendritic cells in JDM of either long or short dis-
ease duration (B, D). Muscle from healthy children
displayed an absence of mature dendritic cells (E), but a
similar display of BDCA2 positive cells (F) compared with
JDM.
Vasculature remodelling in JDM patients
Based on the array data, genes involved in vasculature
remodelling, including the structural gene, SMMHC (two
probe sets, 7.9 and 6.4 folds, p < 0.005), and regulatory
factors, tenomodulin (13.1 fold, p < 0.001), prostaglan-
din E receptor 4 (1.9 fold, p < 0.005), plexin D1 (1.6 fold,
p < 0.001), Akt-3 (1.3 fold, p < 0.001), clusterin (2.9 fold,
p < 0.001), and LPGDS (two probe sets, 2.4 and 1.9 folds,
p < 0.005) [12-19], were significantly differentially
expressed between patients with long and short duration
of active disease, suggesting the involvement of vascula-
ture remodelling during this period of time (Table 3 and
4). In addition, matrix metalloproteinase 2 (2.0 fold, p <
0.005) and collagen VIα2 (1.6 fold, p < 0.005) were also
up-regulated indicating extracellular matrix remodelling,
which is part of angiogenesis [20,21]. Interestingly, most
of these genes belonged to cluster F, in which genes were
down-regulated more in patients with short duration of
active disease when comparing to the baseline (Figure 1,
cluster F), suggesting that the expression changes of these
specific genes were preferentially misregulated in the ear-
lier stage of the inflammatory disease process.
Using qRT-PCR, we confirmed the higher expression of 4
genes related to vascular remodelling in muscle biopsies
of girls with longer disease duration compared with dis-
ease of short duration. The expression level of smooth
muscle heavy chain myosin was elevated 5.9 fold (p <
0.05), clusterin was 4.74 fold increased (p < 0.05); the
level of plexin D1 was increased in the long duration
group by 2.35 fold (p < 0.005), and tenomodulin was
increased by 4.6 fold, (p < 0.05) (Figure 2).
A regression analysis was performed of 79 genes and 9
genes (10 probe sets) were identified that had a statisti-
cally significant linear relationship between the level of
gene expression and duration of active disease (Table 5).
Both probe sets representing SMMHC showed linear rela-
tionships, suggesting that the gene expression changes are
dependent on the duration of the chronic inflammation
of active disease.
Discussion
Impact of duration of untreated inflammation on clinical 
and laboratory findings in children with JDM
Previous studies have confirmed the observation that pro-
longed duration of untreated symptoms in children with
JDM are highly associated with the development of path-
ologic calcifications, one of the most debilitating compli-
cations of JDM [22,23]. Untreated children with a longer
duration of chronic symptoms had a higher frequency of
loss of nailfold capillary end row loops [24], which per-
sisted after 36 months of therapy [25]. The chronic
inflammation associated with nailfold capillary loss was
accompanied by impaired absorption of orally adminis-
tered corticosteroids [26]. In addition, chronic untreated
inflammation at diagnosis of JDM was associated with
severe bone loss and an abnormal osteoprotegerin:
RANKL ratio [10]. A study of 166 previously untreated
children with JDM enrolled in a large national NIAMS
JDM Research Registry showed that the clinical presenta-
Gene tree generated by hierarchical clustering based on gene  expression patterns Figure 1
Gene tree generated by hierarchical clustering based 
on gene expression patterns. Genes up-regulated in girls 
with long (≥ 2 m) vs. short (< 2 m) duration of active disease 
were clustered into cluster C, D and F, while down-regulated 
genes were clustered into clusters A, B and E. The color 
codes represent the ratio between each of the JDM group 
compared with the age- and sex-matched control samples.
A
B
Control   JDM (<2m)  (>2m)
Duration of untreated disease
C
D
E
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tion of the children with shorter duration of active JDM
was quite different from those who came to diagnosis
later in their disease course. Children diagnosed early in
the disease course were more likely to be weaker than later
on, and muscle enzymes were more likely to be in the nor-
mal range 2–4.7 months after the child's first symptom
(rash or weakness) [10] which may be associated with dif-
ferential utilization of the TRAIL apoptotic pathway
[10,27]. In this study we used a 2 month cut-off and iden-
tified 79 genes differentially expressed in patients with
short (less than 2 months) and long (greater than 2
months or equal) duration of active disease by expression
profiling. Identifying these changes provide insight con-
Table 3: Up-regulation of immune response genes in skeletal muscles of patients with active JDM longer than 2 months (Cluster C and 
D; genes are in order shown in figure 1)
Affymetrix accession p-value Fold change (long/short) Gene description
Cluster C
203981_s_at 6.2E-03 1.5 ATP-binding cassette, sub-family D (ALD), member 4
210105_s_at 1.5E-03 1.6 FYN oncogene related to SRC, FGR, YES
214430_at 1.4E-03 1.6 galactosidase, alpha
200602_at 6.5E-04 2.0 amyloid beta (A4) precursor protein
201103_x_at 5.7E-03 1.4 hypothetical protein LOC200030
209765_at 2.3E-03 1.6 a disintegrin and metalloproteinase domain 19
216510_x_at 9.6E-04 5.6 immunoglobulin heavy constant gamma 1
201069_at 3.9E-03 2.0 matrix metalloproteinase 2
203473_at 1.1E-04 2.2 solute carrier organic anion transporter family, member 2B1
203742_s_at 1.9E-03 1.5 thymine-DNA glycosylase
205917_at 6.5E-04 1.6 ZNF264
212671_s_at 2.5E-04 5.6 major histocompatibility complex, class II, DQ alpha 1/2
Cluster D
218376_s_at 4.1E-03 2.5 NEDD9 interacting protein with calponin homology and LIM domains
209079_x_at 9.1E-04 1.6 protocadherin gamma subfamily
38671_at 5.9E-04 1.6 plexin D1
201279_s_at 2.0E-03 1.6 disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila)
211066_x_at 6.5E-04 1.6 protocadherin gamma subfamily
215599_at 3.8E-04 2.1 SMA4
205717_x_at 1.8E-03 1.4 protocadherin gamma subfamily
217659_at 1.3E-03 1.6 KIAA0261
212607_at 1.1E-04 1.3 AKT3 (protein kinase B, gamma)
211748_x_at 4.0E-03 2.4 prostaglandin D2 synthase 21 kDa (brain)
215376_at 2.4E-04 1.4 CDNA FLJ12295 fis, clone MAMMA1001818
202259_s_at 1.1E-04 1.6 phosphonoformate immuno-associated protein 5
212187_x_at 2.1E-03 1.9 prostaglandin D2 synthase 21 kDa (brain)
206666_at 3.7E-04 2.5 granzyme K (serine protease, granzyme 3; tryptase II)
217947_at 5.9E-04 1.9 chemokine-like factor super family 6
Table 4: Genes involved in vasculature remodelling were down-regulated in patients with active JDM shorter than 2 months (Cluster F; 
genes are in order shown in figure 1).
Affymetrix accession p-value Fold change 
(long/short)
Gene description
213290_at 4.2E-03 1.6 collagen, type VI, alpha 2
201141_at 2.1E-06 3.2 glycoprotein (transmembrane) nmb
221796_at 1.9E-03 2.0 cDNA clone IMAGE:452016
207695_s_at 1.9E-03 5.8 immunoglobulin superfamily, member 1
201369_s_at 6.7E-04 1.6 zinc finger protein 36, C3H type-like 2
222043_at 1.1E-04 2.9 Clusterin
201497_x_at 1.3E-03 7.9 myosin, heavy polypeptide 11, smooth muscle
207961_x_at 4.9E-04 6.4 myosin, heavy polypeptide 11, smooth muscle
204897_at 1.2E-03 1.9 prostaglandin E receptor 4
220065_at 6.5E-04 13.1 Tenomodulin
205573_s_at 5.0E-04 1.9 sorting nexin 7BMC Immunology 2008, 9:43 http://www.biomedcentral.com/1471-2172/9/43
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cerning the observed differences in clinical phenotypes at
the molecular level over time.
Down regulation of genes involved in protein turnover and 
metabolism
Down-regulation of protein turnover and stress response
genes in skeletal muscles has been associated with muscu-
lar dystrophies and conditions associated with muscle
atrophy [28,29]. In this study, genes involved in both pro-
tein turnover and stress responses were down-regulated
significantly in patients with longer duration of active dis-
ease [see Additional file 1]. The genes encoding heat shock
proteins (eg. heat shock 70 kDa protein 9B and heat shock
40) and genes involved in proteasome functions (eg. pro-
teasome regulatory particle subunit p44S10, ubiquitina-
tion factor E4B, located in cluster A) showed slight
upregulation in the short duration group compared to
controls, but approached the baseline in the long dura-
tion group, reflecting the acute phase of the disease. In
contrast, genes involved in protein synthesis (eg. eukaryo-
tic translation initiation factor 2, mitochondrial ribos-
omal protein S10 and L15) were mildly downregulated in
the short duration group and achieve significant down-
regulation in the long duration group, suggesting contin-
uous suppression of protein synthesis commonly associ-
ated with muscle atrophy. The changes at the molecular
level support the observation of ongoing muscle loss in
untreated patients with JDM. Gene involved in ER stress
response have been previously reported to be differen-
tially expressed in adults with inflammatory myopathies
[30]. In our study, we did not observe significant differ-
ences between the groups, based on the duration of
untreated disease.
Dendritic cell infiltration
The presence of dendritic cells in the muscle of patients
with dermatomyositis was previously reported [31,32].
Recent investigation presented data showing that the
localization and maturation of resident plasmacytoid
dendritic cells in situ in the perivascular areas was essential
to the initiation and perpetuation of muscle inflamma-
tion in juvenile DM [31]. The present study confirms that
the typical pattern of dendritic cell infiltration (with heavy
infiltration surrounding the blood vessels) in JDM is a
progressive process associated with persistent inflamma-
tion without focal infiltration in muscle of patients with
short duration of active disease. Many DC-LAMP positive
dendritic cells were positive for BDCA2, again confirming
that they were of plasmacytoid dendritic cell lineage as
recently reported [31]. Dendritic cells are well character-
ized for efficient antigen presentation to T cells and are
speculated to affect both tolerance and T cell activation
[33]. Models of autoimmunity through activated den-
dritic cells in rheumatoid arthritis and in systemic lupus
erythematosus (SLE) associated with a Type 1 IFN-α/β ini-
tiated response have been proposed by other investigators
[34-36]. In addition, increased expression of IFNα/β
induced genes have been identified in peripheral blood of
children with SLE, systemic onset juvenile rheumatoid
arthritis, and in JDM [37-39]. In this study, we found large
number of dendritic cells in perivascular areas with dense
mononuclear infiltrates in biopsies from children with
longer duration of active disease, which suggested that
dendritic cells might be actively involved in the progres-
sion of the disease by modulating T cells function in the
muscle vasculature.
Vasculature remodelling
Vascular smooth muscle cells (SMCs) are highly plastic
capable of profound alterations in phenotype in response
to changes in local environmental cues [40]. Vascular
injury initiates a transition in the phenotype of vascular
SMCs whereby "contractile" (differentiated) SMCs are
capable of undergoing transient modification to a highly
"synthetic" (dedifferentiated) state. These synthetic vascu-
lar SMCs are migratory, highly proliferative, and play a
critical role in repair of the vascular injury. Upon resolu-
tion of the injury, SMCs reacquire their contractile pheno-
type and associated markers, which include smooth
muscle isoforms of contractile apparatus proteins such as
SMMHC [40]. In this study, we found clusterin, tenomod-
ulin and prostaglandin E receptor 4 were down-regulated
in JDM patients with short disease duration. In contrast,
for children with longer duration of active disease, expres-
sion of these genes approached the baseline, and addi-
Five differentially expressed genes, HLA-DQA1, smooth  muscle myosin heavy chain (SMMHC), clusterin, plexin D1,  and tenomodulin were verified by quantitative RT-PCR, and  their level of expression compared in diagnostic muscle biop- sies from 5 girls with untreated symptoms of JDM for a short  disease duration < 2 months (open bars) and 5 girls with  untreated symptoms of JDM of ≥ 2 months duration (black  bars) Figure 2
Five differentially expressed genes, HLA-DQA1, 
smooth muscle myosin heavy chain (SMMHC), clus-
terin, plexin D1, and tenomodulin were verified by 
quantitative RT-PCR, and their level of expression 
compared in diagnostic muscle biopsies from 5 girls 
with untreated symptoms of JDM for a short disease 
duration < 2 months (open bars) and 5 girls with 
untreated symptoms of JDM of ≥ 2 months duration 
(black bars). * p < 0.05, **p < 0.005.
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Comparisons of dendritic cells in skeletal muscle biopsies from JDM, long and short disease duration, and normal patients Figure 3
Comparisons of dendritic cells in skeletal muscle biopsies from JDM, long and short disease duration, and nor-
mal patients. DC-LAMP is a membrane bound protein produced by mature activated dendritic cells, while BDCA2 is an anti-
gen produced by immature plasmacytoid dendritic cells (both markers are stained dark brown). Long disease duration JDM 
patients displayed a greater overall presence of mature dendritic cells (A) compared to short disease duration JDM patients 
(C). Greater concentrations of mature dendritic cells were found in perivascular and perifasicular regions compared with the 
endomysium. Many mature dendritic cells co-expressed plasmacytoid markers (A, B). No substantiated differences were found 
in the distribution of the BDCA2 positive plasmacytoid dendritic cells in JDM of either long or short disease duration (B, D). 
Normal pediatric muscle displayed an absence of mature dendritic cells with presence of BDCA2 positive cells (E). Images 
were taken at 10× on a Leica Upright Light Microscope. Scale bars represent 10 μm.BMC Immunology 2008, 9:43 http://www.biomedcentral.com/1471-2172/9/43
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tional genes involved in vasculature remodelling were up-
regulated, (plexin D1, Akt-3, LPGDS). These genes are
associated with contractile (differentiated) vascular SMCs.
These data suggest that early in the course of JDM, a rela-
tively high proportion of vascular SMCs at the site of
inflammation are in a synthetic (dedifferentiated or
undifferentiated) state; conversely, as time passes and the
inflammation becomes chronic, vascular SMCs further
differentiate. The linear regression relationship between
the duration of active disease and the SMMHC expression
suggests that the vasculature remodelling in the muscles is
a progressive process associated with disease chronicity
and the duration of active disease. This is consistent with
the documentation of evidence of cardiovascular compro-
mise in older patients who had JDM in childhood [41].
Among the genes involved in vasculature remodelling,
plexin D1 and prostaglandin E receptor 4, are two potent
angiogenic factors [12,19]. Plexin D1 is expressed in vas-
cular endothelial cells of developing blood vessels. Signal-
ling between semaphorin 3E and its receptor plexin D1
controls endothelial cell positioning and the patterning of
the vasculature during embryonic development, and can
negatively regulate angiogenesis as well as activate T cells
[42]. Because the hallmark of JDM is occlusion and oblit-
eration of capillaries and arterioles, it is not surprising that
expression of tenomodulin is increased, for it is overex-
pressed in hypovascular connective tissue. The up-regula-
tion of these genes might underlie the molecular
mechanisms of the vasculature loss and remodelling we
observed in the patients' muscles.
In summary, the findings from this study support the clin-
ical observation that identification of the duration of the
inflammatory process is a critical component in children
with JDM, influencing both the gene expression and the
pathophysiology of the immune responses in children
with active symptoms. Recognition of this variable, which
identifies the chronicity of the process, is important in dis-
secting out factors involved in immune progression and
response.
Conclusion
We conclude that the duration of the chronic inflamma-
tory process in untreated JDM alters mRNA expression
patterns, including both dendritic cell maturation and
vascular remodelling with increased expression of anti-
angiogenic factors. We propose that the duration of the
inflammatory process must be considered when interpret-
ing gene profiling data as well as clinical and laboratory
findings in children with JDM in order to gain insight into
potential modes of intervention. We speculate that inter-
ventions that diminish the antiangiogenic remodelling
present in children with JDM who have a longer duration
of untreated disease may be of benefit.
Methods
Patient population
Age appropriate informed consent was obtained from a
total of 31 girls with definite/probable JDM (IRB# 2002-
11762) and the 4 healthy age and sex-matched controls
(IRB# 2001-11715) who were enrolled in this study. Eth-
ical approval for this study was obtained from the Chil-
dren's Memorial Hospital Institutional Review Board, and
all procedures were carried out in accordance with the
Helsinki Declaration.
All the girls with JDM were negative for myositis specific
or associated antibodies or for antibodies indicating over-
lap syndromes at the time of biopsy, and, as part of their
diagnostic evaluation, had an MRI directed muscle
biopsy. In the first step, 23 muscle biopsies from partially
treated (n = 4) patients and untreated (n = 19) JDM
patients and 4 control biopsies were expression profiled
and used for gene filtering. In the second step, only
untreated JDM patients at the time of muscle biopsy (n =
19, 3 short and 16 long duration) were analyzed statisti-
cally. In the third step, specific genes identified by the
expression profiles were confirmed by testing additional
samples from 8 untreated children with JDM. There was
enough muscle biopsy material from 2 of the rare group
of children with disease duration less than 2 months to be
Table 5: Nine genes (10 probe sets, SMMCH are represented by two probe sets) for which the expression level correlated with the 
duration of untreated duration of JDM
Affymetrix accession Gene description r square p-value Cluster
207961_x_at myosin, heavy polypeptide 11, smooth muscle 0.47 0.002 F
201369_s_at zinc finger protein 36, C3H type-like 2 0.40 0.005 F
203742_s_at thymine-DNA glycosylase 0.39 0.006 C
214430_at galactosidase, alpha 0.34 0.011 C
201497_x_at myosin, heavy polypeptide 11, smooth muscle 0.33 0.013 F
204807_at transmembrane protein 5 0.28 0.025 A
214437_s_at serine hydroxymethyltransferase 2 (mitochondrial) 0.27 0.027 E
215376_at CDNA FLJ12295 fis, clone MAMMA1001818 0.27 0.027 D
202854_at hypoxanthine phosphoribosyltransferase 1 (Lesch-Nyhan syndrome) 0.25 0.034 E
221931_s_at SEH1-like (S. cerevisiae) 0.23 0.042 ABMC Immunology 2008, 9:43 http://www.biomedcentral.com/1471-2172/9/43
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used for qRT-PCR enabling comparison of 5 patients each
with long and short disease duration, as well as immuno-
histochemical studies.
The date of recognition of the first symptom (rash or
weakness) was defined as the "disease onset date". The
"duration of disease" at the time of the muscle biopsy was
defined as the time from disease onset to the date of mus-
cle biopsy. We have reported the results from profile anal-
yses performed using only samples from untreated girls
with JDM; their demographics are presented in Table 1.
Confirmation of the gene profiles by q-RT PCR utilized a
separate set of 5 muscle biopsies from girls with a short
duration of disease (1.4 ± 0.4 SD months), matched with
5 muscle biopsies' from girls with a long duration of
untreated symptoms (6.8 ± 3.5 SD months); 2 children
tested were also part of the gene profile long duration
group. The girls were matched for age (8.2 ± 2.2 years
compared with 9.5 ± 3.5 years), as well as disease activity,
with respect to DAS skin (5.4 ± 0.9, 5.8 ± 1.5 respectively)
and DAS muscle (8.2 ± 0.8, 8.0 ± 1.2 respectively). Details
are presented in table 2.
The four control muscle from non-inflammatory female
donors were biopsies, obtained with informed consent,
from thoracic muscle from girls undergoing plastic sur-
gery for repair of cleft palate, which do not appear to have
evidence of the genetic dysregulation observed in JDM
[43]. Their age range was 8–10.3; their mean age was 9.5
years.
Disease Activity Scores
Overall measure of severity of the JDM disease activity was
assessed at the time of the diagnostic muscle biopsy using
the total disease activity score (DAS), a 20 point scale
which has two sub-scales, which reflect skin involvement
(ranging from 0–9) and muscle inflammation (ranging
from 0–11) [4]. The skin component (DAS skin) is based
on extent and severity of rash, the presence of telangiecta-
sia (nailfold, palate, eyelids) and Gottron's papules [4]
The muscle component (DAS muscle) includes measures
of muscle function and the extent of weakness in eight
manoeuvres as evaluated by a single physician (LMP) on
routine diagnostic physical examination. Both sub scores
have been validated for inter-rater reliability.
Muscle biopsy samples
A diagnostic muscle biopsy, frequently the vastus lateralis,
was obtained from the area of inflammation as defined by
an MRI, using a T-2 weighted image with fat suppression.
The sample was divided so that one portion was saved for
immunohistochemical studies, while the other portion of
the sample was used for gene expression profile studies
and gene confirmation. Both parts of the muscle biopsy
samples were snap frozen and stored in liquid nitrogen (-
180°C).
Determination of DQA1*0501 and DQA1*0301
At the diagnostic visit, immediately prior to the muscle
biopsy, peripheral blood mononuclear cells were
obtained by Ficoll-Hypaque separation, and frozen in liq-
uid nitrogen at -180°C.
Genomic DNA was extracted from whole blood or frozen
lymphocytes using the Puregene DNA Purification Kit
(Gentra Systems, Minneapolis, MN). DNA from JDM
patients was genotyped for HLA-DQA1*0301 and HLA-
DQA1*0501 alleles using PCR amplification with
sequence-specific primers as previously reported [44,45].
Aliquots of DNA (2 μl) were amplified using TaqBead™
Hot Start Polymerase wax beads (1.25 U/bead; Promega
Corporation, Madison, WI) in a reaction volume of 50 μl
that contained 5× Green GoTaq™ Reaction Buffer
(Promega Corporation, Madison, WI), dNTPs (0.2 mM
each), and 0.4 μM allele specific primers for HLA-
DQA1*0301 or HLA-DQA*0501.
The primers for HLA-DQA1*0301 were: 5'-TTCACTCGT-
CAGCTGACCAT-3' (Forward) and 5'-CAAATTGCGGGT-
CAAATCTTCT-3' (Reverse), which amplify a 183 bp
product. The primers for HLA-DQA*0501 were: 5'-ACG-
GTCCCTCTGGCCAGTA-3' (Forward) and 5'-AGTT-
GGAGCGTTTAATCAGAC-3' (Reverse), which amplify a
186 bp product.
Denaturation was performed in each PCR at 94°C for 45
seconds, annealing at 62°C for 45, and extension at 72°C
for 2 min (for the final step, extension was for 7 min).
Absence or presence of PCR products was visualized by
agarose gel electrophoresis.
Determination of the TNF-α-308 polymorphism
The TNF-α-308 polymorphism consists of a single base
pair G to A substitution. PCR was used to amplify a 107
bp fragment that incorporated the polymorphic site into
an NcoI restriction site as previously described [23,45]
distinguishes AA from AG from GG.
Expression profiles of JDM patient muscle biopsies
Total RNA was isolated from each biopsy, processed for
production of biotinylated cRNA and hybridization to
microarrays, as we have previously described [28]. Each
sample was then hybridized to Affymetrix U133A micro-
arrays containing approximately 14,500 well-character-
ized transcripts. Standard operating procedure and quality
control was done as previously described [46]. Muscle
samples from 23 female JDM patients and 4 healthy age-
and sex-matched controls were initially profiled.BMC Immunology 2008, 9:43 http://www.biomedcentral.com/1471-2172/9/43
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Generation of hybridization signals (probe set algo-
rithms) of the microarrays was done using Affymetrix
MAS (Version 5.0) (Affymetrix, CA), and dCHIP [47].
After the absolute analysis, the gene expression levels were
imported into GeneSpring software. The JDM samples
were normalized to the mean of the profiles of age- and
sex-matched control samples. Data filtering was done by
retaining only those probe sets that showed at least two
MAS5.0 "present calls" across all profiles. This resulted in
retention of 67% of probe sets for the U133A microarrays.
Welch t-test was used to calculate the probabilities of sig-
nificant gene expression changes between samples with
shorter (< 2 months) and longer (≥ 2 months) disease
duration. To reduce false positives, correction for multiple
testing was done using Benjamini and Hochberg false dis-
covery rate (5%) [48,49]. In addition, we used all treated
and untreated patients to first generate a gene list with
genes that showed statistically significant changes to
reduce number of genes for multiple testing. We then used
only the profiles of untreated patients and performed t-
tests on the filtered genes with multiple testing corrections
to minimize the false positives. To visualize transcripts
showing coordinate regulation as a function of active dis-
ease duration, genes sharing temporal patterns were iden-
tified by hierarchical clustering using GeneSpring
software. Clustering algorithm was based on standard cor-
relation (r = 0.95). For hierarchical clustering, we
included all genes with p < 0.05 after multiple testing cor-
rection. In order to determine the presence of significant
linear relationships between gene expression and dura-
tion of untreated disease, linear regression was performed
between the gene expression levels of each of the 79 genes
and duration of untreated disease. All profiles are publicly
accessible via NCBI GEO http://www.ncbi.nlm.nih.gov/
geo/ (GSE11971).
Quantitative Real Time-PCR verification (qRT-PCR)
Total cellular RNA was extracted using Trizol Reagent
(Invitrogen Corp.) and subsequently DNase treated using
DNA-free (Ambion, Austin, TX). Reverse transcription
reactions were performed using Superscript III Reverse
Transcriptase (Invitrogen Corp., Carlsbad, CA) and ran-
dom hexamer primers. Relative cDNA quantification of
smooth muscle myosin heavy chain (SMMHC), clusterin
and an internal reference gene, β-actin, were done using a
TaqMan PCR Core Reagent Kit (Applied Biosystems;
Roche Molecular Systems, Inc., New Jersey) using fluores-
cence-based detection method (Applied Biosystems 7500
Fast Real-Time PCR System; Applied Biosystems, Foster
City, CA). The PCR reaction was performed using stand-
ard methodology as previously described for each gene of
interest and the β-actin reference gene was used to nor-
malize input cDNA.
The primers and probe for SMMHC are as follows: 5'-
CTGGGCAACGTAGTAAAACC-3' (Forward), 5'-TAT-
AGCTCATTGCAGCCTCG-3' (Reverse), and 6FAM-
ATAAGCTGGGCGTGGTGGTACACACCT-TAMRA
(Probe) [50].
The primers and probe for Clusterin are as follows: 5'-
GAGCAGCTGAACGAGCAGTTT-3' (Forward) 5'-
CTTCGCCTTGCGTGAGGT-3' (Reverse) and 6FAM-ACT-
GGGTGTCCCGGCTGGCA-TAMRA (Probe) [51]
The primers and probe for β-actin are as follows: 5'-
TGAGCGCGGCTACAGCTT-3' (Forward) 5'-TCCTTAAT-
GTCACGCACGATTT-3' (Reverse) and 6FAM-ACCAC-
CACGGCCGAGCGG-TAMRA (Probe) [52]
For relative cDNA quantification of class II antigen, HLA-
DQA1 (#QT00060130), plexin D1 (#QT00036134), ten-
omodulin (#QT01024590), and an internal reference
gene, β-actin (#QT00095431), QuantiTect Primer Assays
and QuantiFast Syber Green PCR kits (Qiagen Inc., Valen-
cia, CA) were used (Applied Biosystems 7500 Fast Real-
Time PCR System; Applied Biosystems, Foster City, CA).
The PCR reaction was performed according to manufac-
turer's protocol for these genes using β-actin reference
gene to normalize input cDNA.
Immunohistochemistry assay for mature dendritic cells
Three untreated girls with long duration of active JDM,
were age-race matched with three girls with duration of
untreated symptoms of less than 2 months and 3 age-
matched healthy female muscle donors and studied for
presence of mature dendritic cells. Serial 6 um-thick fro-
zen muscle sections were fixed in cold anhydrous acetone.
Sections were then blocked for 30 minutes in 10% normal
goat or donkey sera and incubated with primary antibody
overnight at 4°C. Monoclonal antibodies against DC-
LAMP (Beckman coulter, CA), raised in mice, were used at
a dilution of 1:10. Polyclonal antibody against BDCA2
(Santa Cruz Biotechnology, CA), raised in goats, were
used at a dilution of 1:50. After 3 washes with 1× PBS,
slides were incubated for 1 hour at room temperature with
biotin conjugated secondary antibodies against mouse
and goat respectively (Jackson Immunoresearch, PA).
Subsequently, slides were stained with Vectastain Elite
(Vector Laboratories, CA), followed by a BioGenex Liquid
DAB Substrate Kit (yielding brown coloration at site of
positive antibody binding). The slides were then counter-
stained with haematoxylin and Scott's bluing solution
(Ricca Chemical, Texas), dehydrated, and prepared for
viewing.
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